KRAS ctDNA Is Predictor of Metastasis and Survival in Pancreatic Cancer
A Mayo Clinic study found that detecting KRAS ctDNA in pancreatic cancer patients signals a higher risk of cancer spread and poorer survival.
Read MorePosted by Chris Wolski | Mar 19, 2025 | Pancreatic |
A Mayo Clinic study found that detecting KRAS ctDNA in pancreatic cancer patients signals a higher risk of cancer spread and poorer survival.
Read MorePosted by Chris Wolski | Mar 12, 2025 | Sequencing Systems |
Children’s Hospital Colorado’s new in-house whole-genome sequencing lab is revolutionizing patient care by making genetic testing faster.
Read MorePosted by Chris Wolski | Mar 12, 2025 | Pancreatic |
Researchers have identified race-associated differences in pancreatic cancer, highlighting the need for diverse clinical trial participation.
Read MorePosted by Chris Wolski | Mar 11, 2025 | Company News |
NeoGenomics, Inc. has acquired Pathliine, expanding its oncology testing services and accelerating growth in other testing.
Read MorePosted by Chris Wolski | Mar 10, 2025 | Cancer |
A new study highlights the role of tsRNAs as potential biomarkers and therapeutic targets for digestive tract diseases.
Read More